Bafna Pharmaceuticals, a Chennai-based pharma company engaged in the manufacturing of pharmaceutical formulations of Betalactum and Non-Betalactum, today announced an addition of a product approval to its kitty.
Following the recent approval of Amlodipine 5 mg and Amlodipine 10 mg, Bafna Pharma has now received the 14th approval from UK Medicines and Healthcare Products Regulatory Agency (MHRA) to manufacture Finasteride 5 mg. Finasteride is used in Benign Prostatic Hypertrophy (BPH) or enlargement of the prostate gland.
Commenting on the approval, Mahaveer Chand Bafna, chairman and managing director, Bafna Pharmaceuticals Ltd said, “For patients with BPH whose disease is worsening and whose symptoms are moderate-to-severe, Finasteride offers the benefits of both medicine, and provides doctors with an effective treatment option. Bafna Pharma has been constantly upgrading its manufacturing facilities to efficiently meet the anticipated demands of the global markets. The approval from UK MHRA for Finasteride 5 mg will enable Bafna Pharma to widen customer base in Europe.”
Finasteride 5mg tablets is a prescription-only medicine (POM) used for the treatment and control of Benign Prostatic Hyperplasia in order to cause regression of an enlarged prostate and improvement of other symptoms associated with BPH. It is also used to reduce the need for BPH-related surgical procedures in patients.
Finasteride is an orally-active testosterone 5-alpha-reductase inhibitor. It is an azasteroid, a synthetic anti-androgen that acts by inhibiting type-2 isoform of 5?-reductase the enzyme that converts testosterone to dihydro testosterone.
It is used as a surgical alternative for treatment of Benign Prostatic Hyperplasia (BPH). In patients with BPH, it reduces dihydrotestosterone concentrations in blood and consequently reduces prostatic volume and improves urinary flow. Finasteride reduces prostatic size by a combination of atrophy and apoptosis. It also reduces detrusor pressure in patients with bladder outlet obstruction by BPH.
